The trial design change improves the near-term regulatory pathway for PDS0101, potentially accelerating value inflection, but the shrinking cash balance (~$26.7M) relative to operating costs (~$31.5M in 2025) suggests a capital raise is likely within the next 9–12 months, which would be dilutive. Monitor upcoming clinical updates on PDS01ADC and enrollment progress in the amended VERSATILE-003 trial.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 30 $0.5370entry
- T+1 · 8mo ago +12.66%α +9.77% · $0.6050
- T+5 · 7mo ago +70.95%α +66.65% · $0.9180
- T+20 · 7mo ago +101.12%α +88.52% · $1.08
- T+60 · 5mo ago +66.48%α +49.99% · $0.8940
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendment for its lead candidate PDS0101 to incorporate progression-free survival as an interim primary endpoint, which could enable accelerated approval in HPV16-positive head and neck cancer. The company reduced operating expenses and improved net loss compared to 2024, but ended the year with $26.7 million in cash, down from $41.7 million, raising concerns about runway. Early data from a PDS01ADC trial showed promising median PFS of 9.6 months in prostate cancer.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $34.5 million ($0.74/share), improved from $37.6 million ($1.03/share) in 2024.
- R&D expenses decreased to $19.0 million from $22.6 million in 2024, driven by lower manufacturing and personnel costs.
- Cash balance declined to $26.7 million as of December 31, 2025, from $41.7 million in 2024, a 36% reduction.
- Amended VERSATILE-003 Phase 3 trial to include PFS as an interim primary endpoint to potentially accelerate approval for PDS0101.
- Early PDS01ADC + docetaxel data in mCRPC showed 9.6 months median PFS and 40% median PSA decline.
- New U.S. and Japanese patents extend PDS0101 IP protection into the 2040s.
Financial Impact
Reduced annual operating expenses by $4.8 million, but cash burn remains high at ~$15 million net reduction in cash year-over-year.
Risk Factors
- Cash runway may be insufficient to reach key milestones without dilutive financing.
- Accelerated approval pathway depends on PFS data, which may not confirm OS benefit.
- Forward-looking statements dominate messaging; clinical progress remains early-stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264482 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers